You can use an at-home blood pressure monitor or work with your healthcare provider to track your progress
Weeks 1-16 follow an initial dose escalation schedule, while the full dose is reached at week 17 of administration, as follows [5]: Weeks 1-4: 0.25mg subcutaneously once weekly
Use of these names does not imply endorsement
Lilly has said seven additional Phase 3 trials in obesity and type 2 diabetes are expected to complete in 2026
You may not be a suitable candidate if you: Are pregnant, planning pregnancy, or breastfeeding Have a personal or family history of medullary thyroid carcinoma (MTC) Have Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Have experienced pancreatitis, depending on your medical history and physician assessment Have certain gastrointestinal disorders or other conditions that may affect treatment safety Your physician will also review your current medications, BMI, medical history, weight-related health conditions, and treatment goals before recommending semaglutide as part of an individualized obesity management plan